Anti-tumor immunotherapy

摘要

The present invention relates to the use of telomerase-derived peptides for the treatment of any cancer patients, particularly for the treatment of patients with renal or prostate cancer.

主权项

1. A therapeutic method for the treatment of a cancer expressing human telomerase, comprising the following steps:
A) administering to a subject in need thereof an antitumoral effective amount of 4 peptides from human telomerase wherein said peptides are:
(i) one HLA class I restricted peptide having the following amino acid sequence ILAKFLHWL (SEQ ID NO. 1),(ii) Three HLA class II restricted peptides having the following amino acid sequences: RPGLLGASVLGLDD1 (SEQ ID NO. 2), LTDLQPYMRQFVAHL (SEQ ID. NO. 3) and EARPALLTSRLRFIKP (SEQ ID. NO. 4), in the form of sterile water/oil emulsion wherein the oil component is an adjuvant and consists of: from 88 to 92% by weight of a white mineral oil identified with the CAS Registry No. 8042-47-5, and from 8 to 12% by weight of mannide monooleate, B) administering to the same subject Imiquimod as a further adjuvant, before, contemporaneously or after (A), at the site wherein respectively step (A) will be, is being or was carried out.